tramiprosate has been researched along with Acute Confusional Senile Dementia in 32 studies
tramiprosate: GABA receptor agonist and a glycosaminoglycan mimetic; has nootropic acitivity; structure; a sulfonate analog of GABA
3-aminopropanesulfonic acid : An amino sulfonic acid that is the 3-amino derivative of propanesulfonic acid.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Tramiprosate has been found to inhibit β-amyloid oligomer formation by a multi-ligand enveloping mechanism of action that stabilizes Aβ42 monomers, resulting in the inhibition of formation of oligomers and subsequent aggregation." | 2.87 | Clinical Pharmacokinetics and Safety of ALZ-801, a Novel Prodrug of Tramiprosate in Development for the Treatment of Alzheimer's Disease. ( Abushakra, S; Amedio, J; Hey, JA; Kaplan, PL; Kocis, P; Power, A; Tolar, M; Versavel, M; Yu, JY, 2018) |
| " Furthermore, in rat preclinical studies, 3-SPA displayed 100% oral bioavailability and 25% brain penetration, indicating that the metabolite is well absorbed and crosses the blood-brain barrier." | 2.87 | Discovery and Identification of an Endogenous Metabolite of Tramiprosate and Its Prodrug ALZ-801 that Inhibits Beta Amyloid Oligomer Formation in the Human Brain. ( Abushakra, S; Hey, JA; Hort, J; Kocis, P; Power, A; Tolar, M; Vyhnálek, M; Yu, JY, 2018) |
| "Academic Alzheimer's disease centers, community-based memory clinics, and neuropsychiatric research sites." | 2.84 | Clinical Effects of Tramiprosate in APOE4/4 Homozygous Patients with Mild Alzheimer's Disease Suggest Disease Modification Potential. ( Abushakra, S; Cummings, J; Gauthier, S; Hey, JA; Porsteinsson, A; Power, A; Sadowsky, C; Scheltens, P; Shen, L; Tolar, M; Vellas, B; Wang, P, 2017) |
| " While there were no statistically significant group differences in hippocampus volume using the First modeling approach, a significant dose-response reduction in hippocampus volume change was found in the Final models." | 2.74 | Effect of tramiprosate in patients with mild-to-moderate Alzheimer's disease: exploratory analyses of the MRI sub-group of the Alphase study. ( Aisen, PS; Duong, A; Ferris, SH; Garceau, D; Gauthier, S; Haine, D; Lau, W; Oh, J; Sampalis, J; Saumier, D; Suhy, J, 2009) |
| "Alzheimer's disease is the most common form of dementia, that affects millions of people worldwide." | 2.61 | Structure and Function of Alzheimer's Amyloid βeta Proteins from Monomer to Fibrils: A Mini Review. ( Agrawal, N; Skelton, AA, 2019) |
| "Tramiprosate is a glycosaminoglycan (GAG) mimetic designed to interfere with the actions of Abeta early in the cascade of amyloidogenic events." | 2.43 | Tramiprosate. ( Wright, TM, 2006) |
| "Homotaurine is a potential therapeutic compound for treatment of Alzheimer's disease (AD), but its efficacy is still under investigation." | 1.72 | IL-33 and IL-10 Serum Levels Increase in MCI Patients Following Homotaurine Treatment. ( Banaj, N; Bossù, P; Golesorkhtafti, S; Lembo, M; Messina, B; Sireno, L; Spalletta, G; Toppi, E, 2022) |
| "With the surge in the cases of Alzheimer's disease (AD) over the years, several targets have been explored to curb the disease." | 1.56 | Dual targeting of cholinesterase and amyloid beta with pyridinium/isoquinolium derivatives. ( Chakravarty, H; Chen, WH; Ju, Y; Tam, KY, 2020) |
| " 3xTg-AD mice (10-month-old) were dosed intraperitoneally with 9R (daily 3, 10 or 30 mg/kg) for a month." | 1.56 | 9R, the cholinesterase and amyloid beta aggregation dual inhibitor, as a multifunctional agent to improve cognitive deficit and neuropathology in the triple-transgenic Alzheimer's disease mouse model. ( Ju, Y; Tam, KY, 2020) |
| "Tramiprosate is a small-molecule Aβ anti-aggregation agent that was evaluated in phase III clinical trials for AD but did not meet the primary efficacy endpoints; however, a pre-specified subgroup analysis revealed robust, sustained, and clinically meaningful cognitive and functional effects in patients with AD homozygous for the ε4 allele of apolipoprotein E4 (APOE4/4 homozygotes), who carry an increased risk for the disease." | 1.46 | Elucidating the Aβ42 Anti-Aggregation Mechanism of Action of Tramiprosate in Alzheimer's Disease: Integrating Molecular Analytical Methods, Pharmacokinetic and Clinical Data. ( Blennow, K; Fillit, H; Hey, JA; Kocis, P; Ray, S; Sinko, W; Tolar, M; Yu, J, 2017) |
| " An anti-amyloidogenic bis-styrylbenzene derivative, KMS80013, showed excellent oral bioavailability (F=46." | 1.39 | Therapeutic and pharmacokinetic characterizations of an anti-amyloidogenic bis-styrylbenzene derivative for Alzheimer's disease treatment. ( Ahn, YG; Byeon, SR; Jeon, M; Kim, DJ; Kim, HV; Kim, HY; Kim, MS; Kim, YS; Kong, JY, 2013) |
| "Taurine is an abundant aminoacid present in brain." | 1.34 | Taurine, an inducer for tau polymerization and a weak inhibitor for amyloid-beta-peptide aggregation. ( Avila, J; Hernández, F; Moreno, FJ; Santa-María, I, 2007) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 9 (28.13) | 29.6817 |
| 2010's | 17 (53.13) | 24.3611 |
| 2020's | 6 (18.75) | 2.80 |
| Authors | Studies |
|---|---|
| Bulic, B | 1 |
| Pickhardt, M | 1 |
| Mandelkow, E | 1 |
| Byeon, SR | 1 |
| Kim, HV | 1 |
| Jeon, M | 1 |
| Ahn, YG | 1 |
| Kim, MS | 1 |
| Kong, JY | 1 |
| Kim, HY | 1 |
| Kim, YS | 1 |
| Kim, DJ | 1 |
| Oumata, N | 1 |
| Lu, K | 1 |
| Teng, Y | 1 |
| Cavé, C | 1 |
| Peng, Y | 1 |
| Galons, H | 1 |
| Roques, BP | 1 |
| Toppi, E | 1 |
| Sireno, L | 1 |
| Lembo, M | 1 |
| Banaj, N | 1 |
| Messina, B | 1 |
| Golesorkhtafti, S | 1 |
| Spalletta, G | 1 |
| Bossù, P | 1 |
| Nemergut, M | 1 |
| Marques, SM | 1 |
| Uhrik, L | 1 |
| Vanova, T | 1 |
| Nezvedova, M | 1 |
| Gadara, DC | 1 |
| Jha, D | 1 |
| Tulis, J | 1 |
| Novakova, V | 1 |
| Planas-Iglesias, J | 1 |
| Kunka, A | 1 |
| Legrand, A | 1 |
| Hribkova, H | 1 |
| Pospisilova, V | 1 |
| Sedmik, J | 1 |
| Raska, J | 1 |
| Prokop, Z | 1 |
| Damborsky, J | 1 |
| Bohaciakova, D | 1 |
| Spacil, Z | 1 |
| Hernychova, L | 1 |
| Bednar, D | 1 |
| Marek, M | 1 |
| Chakravarty, H | 1 |
| Ju, Y | 2 |
| Chen, WH | 1 |
| Tam, KY | 2 |
| Zou, X | 1 |
| Himbert, S | 1 |
| Dujardin, A | 1 |
| Juhasz, J | 1 |
| Ros, S | 1 |
| Stöver, HDH | 1 |
| Rheinstädter, MC | 1 |
| Kocis, P | 3 |
| Tolar, M | 4 |
| Yu, J | 1 |
| Sinko, W | 1 |
| Ray, S | 1 |
| Blennow, K | 2 |
| Fillit, H | 1 |
| Hey, JA | 4 |
| Yu, JY | 2 |
| Versavel, M | 1 |
| Abushakra, S | 3 |
| Power, A | 3 |
| Kaplan, PL | 1 |
| Amedio, J | 1 |
| Porsteinsson, A | 1 |
| Scheltens, P | 1 |
| Sadowsky, C | 1 |
| Vellas, B | 2 |
| Cummings, J | 1 |
| Gauthier, S | 3 |
| Wang, P | 2 |
| Shen, L | 1 |
| Liu, Y | 1 |
| Xu, LP | 1 |
| Wang, Q | 1 |
| Yang, B | 1 |
| Zhang, X | 1 |
| Hort, J | 1 |
| Vyhnálek, M | 1 |
| Agrawal, N | 1 |
| Skelton, AA | 1 |
| Ding, K | 1 |
| Brener, O | 1 |
| Dunkelmann, T | 1 |
| Gremer, L | 1 |
| van Groen, T | 1 |
| Mirecka, EA | 1 |
| Kadish, I | 1 |
| Willuweit, A | 1 |
| Kutzsche, J | 1 |
| Jürgens, D | 1 |
| Rudolph, S | 1 |
| Tusche, M | 1 |
| Bongen, P | 1 |
| Pietruszka, J | 1 |
| Oesterhelt, F | 1 |
| Langen, KJ | 1 |
| Demuth, HU | 1 |
| Janssen, A | 1 |
| Hoyer, W | 1 |
| Funke, SA | 1 |
| Nagel-Steger, L | 1 |
| Willbold, D | 1 |
| Habchi, J | 1 |
| Arosio, P | 1 |
| Perni, M | 1 |
| Costa, AR | 1 |
| Yagi-Utsumi, M | 1 |
| Joshi, P | 1 |
| Chia, S | 1 |
| Cohen, SI | 1 |
| Müller, MB | 1 |
| Linse, S | 1 |
| Nollen, EA | 1 |
| Dobson, CM | 1 |
| Knowles, TP | 1 |
| Vendruscolo, M | 1 |
| Rozga, M | 1 |
| Bittner, T | 1 |
| Höglund, K | 1 |
| Saumier, D | 4 |
| Aisen, PS | 3 |
| Ferris, SH | 2 |
| Duong, A | 3 |
| Suhy, J | 2 |
| Oh, J | 2 |
| Lau, W | 2 |
| Garceau, D | 4 |
| Haine, D | 3 |
| Sampalis, J | 3 |
| Martineau, E | 1 |
| de Guzman, JM | 1 |
| Rodionova, L | 1 |
| Kong, X | 1 |
| Mayer, PM | 1 |
| Aman, AM | 1 |
| Shitaka, Y | 1 |
| Mitani, Y | 1 |
| Nagakura, A | 1 |
| Miyake, A | 1 |
| Matsuoka, N | 1 |
| Caltagirone, C | 1 |
| Ferrannini, L | 1 |
| Marchionni, N | 1 |
| Nappi, G | 1 |
| Scapagnini, G | 1 |
| Trabucchi, M | 1 |
| Wright, TM | 1 |
| Briand, R | 1 |
| Laurin, J | 1 |
| Gervais, F | 1 |
| Tremblay, P | 1 |
| Melnikova, I | 1 |
| Santa-María, I | 1 |
| Hernández, F | 1 |
| Moreno, FJ | 1 |
| Avila, J | 1 |
| Sugimoto, H | 1 |
| Renner, M | 1 |
| Melki, R | 1 |
| Villegas, S | 1 |
| Geerts, H | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Phase I, Single Centre, Double-Blind, Placebo-Controlled Study of the Safety, Tolerability and Pharmacokinetics in Plasma and Urine of Multiple Ascending Doses of ALZ-801 in Healthy Elderly Subjects[NCT04157712] | Phase 1 | 48 participants (Actual) | Interventional | 2015-09-26 | Completed | ||
| Four-Period, Single-Dose, Sequential Study in Healthy Adults, to Assess Pharmacokinetics of ALZ-801 and Tramiprosate From ALZ-801 Prototype Tablets and Effect of Food on Bioavailability of ALZ-801 and Tramiprosate for Selected Prototype Tablet[NCT04585347] | Phase 1 | 12 participants (Actual) | Interventional | 2015-09-16 | Completed | ||
| A Phase 1b, 12-Month, Randomized, Double-Blind, Placebo-Controlled Study of the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of Salsalate in Patients With Mild to Moderate Alzheimer's Disease[NCT03277573] | Phase 1 | 40 participants (Anticipated) | Interventional | 2017-07-21 | Active, not recruiting | ||
| Pre-Clinical Alzheimer's (ALZ) Diagnosis (PCD) = Optimum Outcomes (OO)[NCT02835716] | 150 participants (Anticipated) | Observational [Patient Registry] | 2016-09-30 | Recruiting | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
11 reviews available for tramiprosate and Acute Confusional Senile Dementia
| Article | Year |
|---|---|
Progress and developments in tau aggregation inhibitors for Alzheimer disease.
Topics: Alzheimer Disease; Animals; Clinical Trials as Topic; Humans; Hydrogen Bonding; Models, Molecular; P | 2013 |
Molecular mechanisms in Alzheimer's disease and related potential treatments such as structural target convergence of antibodies and simple organic molecules.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Amyloid beta-Protein Precursor; Amyloid Precursor Protein | 2022 |
Structure and Function of Alzheimer's Amyloid βeta Proteins from Monomer to Fibrils: A Mini Review.
Topics: Alzheimer Disease; Amyloid; Amyloid beta-Peptides; Antibodies, Monoclonal, Humanized; Clinical Trial | 2019 |
Proteoglycans and glycosaminoglycans in misfolded proteins formation in Alzheimer's disease.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Clinical Trials as Topic; Glycosaminoglycans; Heparin, Low | 2014 |
[Progress in the development of anti-amyloid drugs for treatment of Alzheimer's disease.].
Topics: Alanine; Alzheimer Disease; Amyloid beta-Peptides; Amyloid beta-Protein Precursor; Amyloid Precursor | 2010 |
The potential protective effect of tramiprosate (homotaurine) against Alzheimer's disease: a review.
Topics: Aged; Alzheimer Disease; Amyloid beta-Peptides; Animals; Brain; Clinical Trials as Topic; Humans; No | 2012 |
Tramiprosate.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Animals; Cognition; Humans; Nootropic Agents; Randomized C | 2006 |
[New approaches for the development of anti-Alzheimer's disease drugs based on the cholinergic hypothesis and amyloid hypothesis].
Topics: Acetylcholine; Acetylcholinesterase; Alzheimer Disease; Amyloid beta-Peptides; Amyloid beta-Protein | 2008 |
Protein aggregation and prionopathies.
Topics: Aging; Alzheimer Disease; Amyotrophic Lateral Sclerosis; Animals; Autophagy; Biopolymers; Clinical T | 2014 |
[Alzheimer's disease: New therapeutic strategies].
Topics: Alzheimer Disease; Amyloid Precursor Protein Secretases; Antibodies, Monoclonal; Cholinergic Antagon | 2015 |
NC-531 (Neurochem).
Topics: Alzheimer Disease; Amyloid beta-Peptides; Animals; Clinical Trials, Phase I as Topic; Clinical Trial | 2004 |
7 trials available for tramiprosate and Acute Confusional Senile Dementia
| Article | Year |
|---|---|
Clinical Pharmacokinetics and Safety of ALZ-801, a Novel Prodrug of Tramiprosate in Development for the Treatment of Alzheimer's Disease.
Topics: Administration, Oral; Adult; Aged; Alzheimer Disease; Area Under Curve; Capsules; Dose-Response Rela | 2018 |
Clinical Pharmacokinetics and Safety of ALZ-801, a Novel Prodrug of Tramiprosate in Development for the Treatment of Alzheimer's Disease.
Topics: Administration, Oral; Adult; Aged; Alzheimer Disease; Area Under Curve; Capsules; Dose-Response Rela | 2018 |
Clinical Pharmacokinetics and Safety of ALZ-801, a Novel Prodrug of Tramiprosate in Development for the Treatment of Alzheimer's Disease.
Topics: Administration, Oral; Adult; Aged; Alzheimer Disease; Area Under Curve; Capsules; Dose-Response Rela | 2018 |
Clinical Pharmacokinetics and Safety of ALZ-801, a Novel Prodrug of Tramiprosate in Development for the Treatment of Alzheimer's Disease.
Topics: Administration, Oral; Adult; Aged; Alzheimer Disease; Area Under Curve; Capsules; Dose-Response Rela | 2018 |
Clinical Effects of Tramiprosate in APOE4/4 Homozygous Patients with Mild Alzheimer's Disease Suggest Disease Modification Potential.
Topics: Aged; Alzheimer Disease; Amyloid beta-Peptides; Apolipoprotein E4; Cognition; Dose-Response Relation | 2017 |
Discovery and Identification of an Endogenous Metabolite of Tramiprosate and Its Prodrug ALZ-801 that Inhibits Beta Amyloid Oligomer Formation in the Human Brain.
Topics: Aged; Alzheimer Disease; Amyloid beta-Peptides; Animals; Brain; Chromatography, Liquid; Cognition Di | 2018 |
Lessons learned in the use of volumetric MRI in therapeutic trials in Alzheimer's disease: the ALZHEMED (Tramiprosate) experience.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Amyloid; Double-Blind Method; Female; GABA Agonists; Hum | 2009 |
Effect of tramiprosate in patients with mild-to-moderate Alzheimer's disease: exploratory analyses of the MRI sub-group of the Alphase study.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Amyloid beta-Peptides; Biomarkers; Cognition; Dose-Respo | 2009 |
Domain-specific cognitive effects of tramiprosate in patients with mild to moderate Alzheimer's disease: ADAS-cog subscale results from the Alphase Study.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Analysis of Variance; Cognition; Dose-Response Relations | 2009 |
A Phase II study targeting amyloid-beta with 3APS in mild-to-moderate Alzheimer disease.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Amyloid beta-Peptides; Brain; Diarrhea; Dose-Response Re | 2006 |
14 other studies available for tramiprosate and Acute Confusional Senile Dementia
| Article | Year |
|---|---|
Therapeutic and pharmacokinetic characterizations of an anti-amyloidogenic bis-styrylbenzene derivative for Alzheimer's disease treatment.
Topics: Administration, Oral; Alzheimer Disease; Aniline Compounds; Animals; Benzene Derivatives; Brain; Dis | 2013 |
IL-33 and IL-10 Serum Levels Increase in MCI Patients Following Homotaurine Treatment.
Topics: Alzheimer Disease; Cognitive Dysfunction; Cytokines; Humans; Interleukin-10; Interleukin-18; Interle | 2022 |
Domino-like effect of C112R mutation on ApoE4 aggregation and its reduction by Alzheimer's Disease drug candidate.
Topics: Alzheimer Disease; Apolipoprotein E3; Apolipoprotein E4; Apolipoproteins E; Humans; Mutation | 2023 |
Dual targeting of cholinesterase and amyloid beta with pyridinium/isoquinolium derivatives.
Topics: Acetylcholinesterase; Alzheimer Disease; Amyloid beta-Peptides; Animals; Catalytic Domain; Cell Line | 2020 |
9R, the cholinesterase and amyloid beta aggregation dual inhibitor, as a multifunctional agent to improve cognitive deficit and neuropathology in the triple-transgenic Alzheimer's disease mouse model.
Topics: Alzheimer Disease; Amyloid beta-Protein Precursor; Animals; Brain Chemistry; Cholinesterase Inhibito | 2020 |
Curcumin and Homotaurine Suppress Amyloid-β
Topics: Alzheimer Disease; Amyloid; Amyloid beta-Peptides; Brain; Curcumin; Humans; Peptide Fragments; Tauri | 2021 |
Elucidating the Aβ42 Anti-Aggregation Mechanism of Action of Tramiprosate in Alzheimer's Disease: Integrating Molecular Analytical Methods, Pharmacokinetic and Clinical Data.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Apolipoprotein E4; Dose-Response Relationship, Drug; Drug | 2017 |
Synergistic Inhibitory Effect of GQDs-Tramiprosate Covalent Binding on Amyloid Aggregation.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Amyloidogenic Proteins; Amyloidosis; Diabetes Mellitus, Ty | 2018 |
QIAD assay for quantitating a compound's efficacy in elimination of toxic Aβ oligomers.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Animals; Carrier Proteins; Catechin; Disease Models, Anima | 2015 |
An anticancer drug suppresses the primary nucleation reaction that initiates the production of the toxic Aβ42 aggregates linked with Alzheimer's disease.
Topics: Alzheimer Disease; Amino Acid Sequence; Amyloid beta-Peptides; Animals; Animals, Genetically Modifie | 2016 |
Accuracy of cerebrospinal fluid Aβ1-42 measurements: evaluation of pre-analytical factors using a novel Elecsys immunosassay.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Antibodies; Cryoprotective Agents; Freezing; Humans; Immun | 2017 |
Investigation of the noncovalent interactions between anti-amyloid agents and amyloid beta peptides by ESI-MS.
Topics: Alzheimer Disease; Amino Acid Sequence; Amyloid beta-Peptides; Humans; Molecular Sequence Data; Mole | 2010 |
Therapies for Alzheimer's disease.
Topics: Alzheimer Disease; Alzheimer Vaccines; Amyloid beta-Peptides; Amyloid Precursor Protein Secretases; | 2007 |
Taurine, an inducer for tau polymerization and a weak inhibitor for amyloid-beta-peptide aggregation.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Humans; Molecular Structure; Neurofibrillary Tangles; Plaq | 2007 |